Herein, cisplatin-loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) nanoparticles were evaluated as a potential chemotherapeutic agent against osteosarcoma by using alone or with an iRGD (internalizing RGD, CRGDKDPDC). The release rate of platinum from the cisplatin-loaded nanoparticles CDDP/PLG160-g-mPEG2K (CDDP-NPs) accelerated with the increase of the acidity of the environment. In vitro test demonstrated that CDDP-NPs could inhibit the proliferation of MNNG/Hos osteosarcoma cells with IC50 (72 h) of 12.2 mu g . mL(-1). In vivo test for MNNG/Hos osteosarcoma tumor bearing mice exhibited that CDDP-NPs had comparable or slightly higher efficacy but significantly lower side effects in comparison with free CDDP. The coadministration of iRGD could further enhance the anticancer efficacy of CDDP-NPs against MNNG/Hos osteosarcoma without bringing obvious side effects. Therefore, CDDP-NPs using alone or with iRGD have great potential for the treatment of osteosarcoma.
[1]Jilin Univ, Dept Orthopaed, Norman Bethune Hosp 1, Changchun 130021, Peoples R China.
[2]Chinese Acad Sci, Changchun Inst Appl Chem, Key Lab Polymer Ecomat, Changchun 130022, Peoples R China.
[3]Jilin Cent Hosp, Jilin 132011, Jilin, Peoples R China.
[4]Beihua Univ, Basic Med Coll, Jilin 132013, Jilin, Peoples R China.
[5]Hosp Jilin Chem Ind Co, Jilin 132021, Jilin, Peoples R China.
(8.0+极速模式)